Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of LF111 4 mg oral contraception in Japanese women
jRCT2031210556Phase 3Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of drospirenone in contraception, sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoint: Overall Pearl Index. Started Jan 2022; status: completed.
02
Drugs
drospirenone
03
Conditions
contraception
Beyond the preview
Go deeper on jRCT2031210556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210556.